. Characteristics of the human trials included in this review: study design, type of participants, control and intervention description, dose and duration of treatment, analyses and related bioavailability studies.
Study Experimental Characteristics

Reference
Clinical trial design (RCT, crossover, parallel) Plasma: ↓VitC, β-car, C1 (post-vs pre-), ↓Lyc C1, C2 (post-vs pre-), ↑β-car, C2 vs T (post-),C2 vs C1 (post-), ↑α-toc C2 vs T (post-) (NC) VitC, folate C2 vs T (post-) [7] Di Renzo L et al., 2014 [8] Randomized, crossover Plasma: ↑n-3 (ALA, EPA), T1 (post-vs pre-) ↓n-6/n-3 ratio, T1 (post-vs pre-) (NC) n-3, n-6 , T2 (post-vs pre-), (NC) DHA , T1, T2, (post -vs pre-) Nuts González-Sarrías A et al., 2010 [30] Randomized, parallel SD (values only in figure) NR NR (7) Texercise (14), Cexercise (13) T (9) vs C (7), Texercise (14) vs Cexercise (13) Change ( Unclear (values only in figure) NR NR ) ; CDKN1B, cyclin dependent kinase inhibitor 1B (alias: p27); COL1A1, collagen type I alpha 1 chain; COL1A2, collagen type I alpha 2 chain; COL3A1, collagen type III alpha 1 chain; CPT1A, carnitine palmitoyltransferase 1A; CPT1B, carnitine palmitoyltransferase 1B; CRAT, carnitine O-acetyltransferase; CTNNB1, catenin beta 1; CXCL8, C-X-C motif chemokine ligand 8 (alias: IL8); CXCR1, C-X-C motif chemokine receptor 1; CXCR2, C-X-C motif chemokine receptor 2 (alias: IL8RA); CYBA, cytochrome B-245 alpha chain (alias: P22-Phox); CYBB, cytochrome B-245 beta chain (alias: NOX2, GP91-Phox); CYP1A1, cytochrome P450 family 1 subfamily A member 1; DSC1, desmocollin 1; DUOX2, dual oxidase 2; ECE2, endothelin converting enzyme 2; EGFR, epidermal growth factor receptor; EGR1, early growth response 1; E2F1, E2F transcription factor 1; ERCC1, ERCC excision repair 1, endonuclease non-catalytic subunit; ERCC2, ERCC excision repair 2, TFIIH core complex helicase subunit; ERCC4, ERCC excision repair 4, endonuclease catalytic subunit; FBXO32, F-box protein 32 (alias: Atrogin1); FOSL1, FOS like 1, AP-1 transcription factor subunit (alias: FRA-1); FXN, frataxin, Friedreich ataxia protein; GCLC, glutamate-cysteine ligase catalytic subunit (alias: γGCL); GCLM, glutamate-cysteine ligase modifier subunit; GJA1, gap junction protein alpha 1; GPX1, glutathione peroxidase 1; GPX4, glutathione peroxidase 4; GPX7, glutathione peroxidase 7; GSTA1, glutathione S-transferase alpha 1; GSTA4, glutathione S-transferase alpha 4; GSTK1, glutathione S-transferase kappa 1; GSTM1, glutathione S-transferase Mu 1; GSTM2, glutathione S-transferase Mu 2; GSTM3, glutathione S-transferase Mu 3; GSTM4, glutathione S-transferase Mu 4; GSTM5, glutathione Stransferase Mu 5; GSTO1, glutathione S-transferase omega 1; GSTO2, glutathione S-transferase omega 2; GSTP1, glutathione S-transferase Pi 1 (alias: GSTP1-1); GSR, glutathione-disulfide reductase (alias: GRD1); GSTT1, glutathione S-transferase theta 1; HAS1, hyaluronan synthase 1; HAS2, hyaluronan synthase 2; HBG1, hemoglobin subunit gamma 1; HMGA1, high mobility group at-hook 1; HMGCR, Table abbreviations (in alphabetical order): C, control group; CI, confidence intervals; CV, coefficient of variation, d, days; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; FC, fold-change; MED1, mediator complex subunit 1 (alias: PPARBP); NR, not reported; post-, after treatment; PPARA, peroxisome proliferator activated receptor alpha; PPARG, peroxisome proliferator activated receptor gamma; PPARD, peroxisome proliferator activated receptor delta; PPARGC1A, PPARG coactivator 1 alpha (alias: PGC1α); pre-, baseline or before treatment; ref gene, reference gene; Res, resveratrol; SD, standard deviation; SEM, standard error of the mean; T, treated group; VitC, vitamin C; VitE, vitamin E. Table S6 . Summary of the expression changes in the GPX family of genes as determined in human cell or tissue samples following intervention with diets, foods or derived products rich in bioactive compounds or with single bioactive compounds. The type and quality of the data presented in the study, estimation of or information about the variability as well as information about the association between the observed effects with the presence of bioactive metabolites and (or) with the corresponding protein quantity/activity are indicated. The↑ is mostly due to large changes only in 2 subjects NR Erythrocytes: ↑GPx-1 activity in T (post-vs pre-) previously reported [7] Marotta F et al, 2010 [39] Fermented papaya (6 g /28 d)
↑GPX1
(neutrophils, n= 11)
• C: not included No effect on GPX1 (neutrophils, n=33)
• C: placebo, data presented as expression levels (data estimated from figure, mean ± SEM) -Post-: 0.7 vs pre-: 1 (arbitrarily referred) • T1: data presented as expression levels (data estimated from figure, mean ± SEM) -Post-: 0.8 vs pre-:1 (arbitrarily referred) • T2: data presented as expression levels (data estimated from figure, mean ± SEM) -Post-: 1.3 vs pre-:1 (arbitrarily referred) • T3: data presented as expression levels (data estimated from figure, mean ± SEM) - Table abbreviations (in alphabetical order): C, control group; CV, coefficient of variation; d, days; FC, fold-change; GPX1, glutathione peroxidase 1; GPX4, glutathione peroxidase 4; GPX7, glutathione peroxidase 7; h, hours; McD, McDonald; Med, Mediterranean; FruVeg, fruits and vegetables; NR, not reported; NS, not significant; post-, after treatment; pre-, baseline or before treatment; SD, standard deviation; SEM, standard error of the mean; Se, selenium; T, treated group; vitC, vitamin C; vitE, vitamin E.
